Clinical trial
A 24 Week Study to Evaluate the Predictive Ability of the COPD Assessment Test (CAT) for Acute Exacerbations (PACE) in Patients With Chronic Obstructive Pulmonary Disease
NCT01254032 is registered in ClinicalTrials.gov with GlaxoSmithKline as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A 24 Week Study to Evaluate the Predictive Ability of the COPD Assessment Test (CAT) for Acute Exacerbations (PACE) in Patients With Chronic Obstructive Pulmonary Disease
- Lead sponsor
- GlaxoSmithKline
- Phase
- Observational
- Overall status
- Completed
- Start date
- August 31, 2010
- Completion date
- November 30, 2011
- Enrollment
- 70 (actual)
- Sites
- 19
Conditions
As the registry lists them; a condition with its own page is linked.